Date: 2015-10-16
Type of information: IPO
Company: Basilea Pharmaceutica (Switzerland)
Investors:
Amount:
Funding type: IPO
Planned used: The principal purposes of this offering are to access the U.S. public equity market, create a public market for its ADS, and increase Basilea\'s financial flexibility. The company intends to use the proceeds from the proposed offering to participate in a U.S. phase 3 development program for ceftobiprole and to support and expand the commercialization of isavuconazole (Cresemba®) and ceftobiprole (Zevtera®/Mabelio®). Cresemba® has been recently approved in the US and in the EU for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis. Zevtera® is already approved in the EU and in Switzerland and the drug has just been approved in Canada. The funds will also support post-approval pediatric studies approved by the EMA for isavuconazole and ceftobiprole in Europe and advance Basilea\'s oncology product candidates and early stage programs. Basilea expects to use the remainder of any net proceeds from this offering for working capital and other general corporate purposes.
Others: * On October 16, 2015, Basilea Pharmaceutica announced that it filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed public offering of common shares in the form of American Depositary Shares (ADS). The shares offered will be issued based on the existing authorization provided by Basilea\'s shareholders. A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Basilea\'s common shares are listed on SIX Swiss Exchange. The company has applied to list the ADS to be offered in the U.S. offering on The Nasdaq Global Market in the United States under the symbol \"BSLN.\"
Therapeutic area: Infectious diseases - Rare diseases
